HYDROXYCHLOROQUINE FOR THE TREATMENT OF SEVERE RESPIRATORY INFECTION BY COVID-19: A RANDOMIZED CONTROLLED TRIAL - Hernandez-Cardenas, Carmen; Thirion-Romero, Ireri; Rivera-Martinez, Norma E.; Meza-Meneses, Patricia; Remigio-Luna, Arantxa; Perez-Padilla, Rogelio; on behalf of the Research Group on hydroxychloroquine for COVID-19 (medRxiv, 2021)
The novel coronavirus pandemic (COVID–19) represents a major public health problem due to its rapid spread and its ability to generate severe pneumonia. Thus, it is essential to find a treatment that reduces mortality. Our objective was to estimate whether treatment with 400 mg/day of Hydroxychloroquine for 10 days reduces in-hospital mortality in subjects with severe respiratory disease due to COVID-19 compared with placebo.Material and methods A double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of Hydroxychloroquine for the treatment of severe disease by COVID-19 through an intention-to-treat analysis. Eligible for the study were adults aged more than 18 years with COVID-19 confirmed by RT-PCR and lung injury requiring hospitalization with or without mechanical ventilation. Primary outcome was 30-day mortality. Secondary outcomes: days of mechanical ventilation, days of hospitalization and cumulative incidence of serious adverse events.Results A total of 214 patients with COVID-19 were recruited, randomized and analyzed. They were hypoxemic with a mean SpO2 of 65% extpm 20, tachycardic (pulse rate 108 extpm17 min-1) and tachypneic (32 extpm10 min-1); 162 were under mechanical ventilation at randomization. Thirty-day mortality was similar in both groups (38% in Hydroxychloroquine vs. 41% in placebo, hazard ratio [HR] 0.88, 95% Confidence Interval [95%CI] 0.51-1.53). In the surviving participants, no significant difference was found in secondary outcomes.Conclusion No beneficial effect or significant harm could be demonstrated in our randomized controlled trial including 214 patients, using relatively low doses of Hydroxychloroquine compared with placebo in hospitalized patients with severe COVID-19.View this table:Competing Interest StatementWe thank all the study participants. Support for the trial was received from the participating hospitals: Instituto Nacional de Enfermedades Respiratorias, Hospital Regional de Alta Especialidad de Ixtapaluca and Hospital de Regional de Alta Especialidad de Oaxaca, and from CONACYT (National Council of Science and Technology of Mexico) and from SANOFI through an investigator-sponsored trial, including the tested drug and identical placebo. The authors designed the trial, performed the analysis and wrote the manuscript.Clinical TrialNCT04315896Funding StatementWe thank all the study participants. Support for the trial was received from the participating hospitals: Instituto Nacional de Enfermedades Respiratorias, Hospital Regional de Alta Especialidad de Ixtapaluca and Hospital de Regional de Alta Especialidad de Oaxaca, and from CONACYT (National Council of Science and Technology of Mexico) and from SANOFI through an investigator-sponsored trial, including the tested drug and identical placebo. The authors designed the trial, performed the analysis and wrote the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The three hospitals that were included in the protocol belong to the same organization, the Coordination of the National Institutes of Health and High Specialty Hospitals, and the protocol was approved by a Single Ethics Committee from the Coordination granting approval with the code C13-20. This report followed the CONSORT 13 guidelines and was also approved by the Institutional Ethics Committee (Research Committee, Research Ethics Committee and Biosafety Committee). The trial was registered with ClinicalTrials.gov (identifier NCT04315896). Every subject who met the inclusion criteria was invited to participate in the protocol, explaining risk and benefits, if the subject agreed to participate, consent was requested and signed either in person or electronically by legal representatives when a participant was unable to sign due to the initiation of mechanical ventilation. If the subject waived the invitation, subject continued the medical attention and with the prescriptions that theirs doctors considered appropriate.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and Code Availability The data and codes related to the findings of this study will be available from the corresponding author after publication, upon reasonable request, especially from investigators compiling hydroxychloroquine studies to treat COVID-19. The group formed by the principal investigators will analyze the quality of the proposal and the security offered for the data. The patient-level data, without individual identifiers, will be shared after approval of the submitted proposal.